142 related articles for article (PubMed ID: 19833833)
1. A new ultraperformance-tandem mass spectrometry oral fluid assay for 29 illicit drugs and medications.
Huestis MA
Clin Chem; 2009 Dec; 55(12):2079-81. PubMed ID: 19833833
[No Abstract] [Full Text] [Related]
2. Simultaneous screening and quantification of 29 drugs of abuse in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS.
Badawi N; Simonsen KW; Steentoft A; Bernhoft IM; Linnet K
Clin Chem; 2009 Nov; 55(11):2004-18. PubMed ID: 19797719
[TBL] [Abstract][Full Text] [Related]
3. Identification and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid chromatography-tandem mass spectrometry.
Fritch D; Blum K; Nonnemacher S; Haggerty BJ; Sullivan MP; Cone EJ
J Anal Toxicol; 2009; 33(9):569-77. PubMed ID: 20040131
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of 75 abuse drugs including amphetamines, benzodiazepines, cocaine, opioids, piperazines, zolpidem and metabolites in human hair samples using liquid chromatography-tandem mass spectrometry.
Shin Y; Kong TY; Cheong JC; Kim JY; Lee JI; Lee HS
Biomed Chromatogr; 2019 Sep; 33(9):e4600. PubMed ID: 31116452
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the diagnostic performance of an oral fluid screening test device for substance abuse at traffic controls.
Avcioglu G; Yilmaz G; Yalcin Sahiner S; Kozaci LD; Bal C; Yilmaz FM
Clin Biochem; 2021 Jul; 93():112-118. PubMed ID: 33882283
[TBL] [Abstract][Full Text] [Related]
6. Performance evaluation of the DrugWipe® 5/5+ on-site oral fluid screening device.
Pehrsson A; Blencowe T; Vimpari K; Impinen A; Gunnar T; Lillsunde P
Int J Legal Med; 2011 Sep; 125(5):675-83. PubMed ID: 20652713
[TBL] [Abstract][Full Text] [Related]
7. Determination of 21 drugs in oral fluid using fully automated supported liquid extraction and UHPLC-MS/MS.
Valen A; Leere Øiestad ÅM; Strand DH; Skari R; Berg T
Drug Test Anal; 2017 May; 9(5):808-823. PubMed ID: 27464485
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of the diagnostic yield of newborn drug testing.
Wood KE; Sinclair LL; Rysgaard CD; Strathmann FG; McMillin GA; Krasowski MD
BMC Pregnancy Childbirth; 2014 Jul; 14():250. PubMed ID: 25073780
[TBL] [Abstract][Full Text] [Related]
9. Comparison of drugs of abuse detection in meconium by EMIT II and ELISA.
Marin SJ; Keith L; Merrell M; McMillin GA
J Anal Toxicol; 2009 Apr; 33(3):148-54. PubMed ID: 19371463
[TBL] [Abstract][Full Text] [Related]
10. QuEChERS sample preparation prior to LC-MS/MS determination of opiates, amphetamines, and cocaine metabolites in whole blood.
Dulaurent S; El Balkhi S; Poncelet L; Gaulier JM; Marquet P; Saint-Marcoux F
Anal Bioanal Chem; 2016 Feb; 408(5):1467-74. PubMed ID: 26753977
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of two LC-MS/MS methods for the detection and quantification of amphetamines, designer amphetamines, benzoylecgonine, benzodiazepines, opiates, and opioids in urine using turbulent flow chromatography.
Schaefer N; Peters B; Schmidt P; Ewald AH
Anal Bioanal Chem; 2013 Jan; 405(1):247-58. PubMed ID: 23076398
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous detection and quantification of amphetamines, diazepam and its metabolites, cocaine and its metabolites, and opiates in hair by LC-ESI-MS-MS using a single extraction method.
Miller EI; Wylie FM; Oliver JS
J Anal Toxicol; 2008 Sep; 32(7):457-69. PubMed ID: 18713513
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of New Psychoactive Substances (NPS) and conventional drugs of abuse (DOA) in high risk populations from Paris (France) and its suburbs: A cross sectional study by hair testing (2012-2017).
Larabi IA; Fabresse N; Etting I; Nadour L; Pfau G; Raphalen JH; Philippe P; Edel Y; Alvarez JC
Drug Alcohol Depend; 2019 Nov; 204():107508. PubMed ID: 31670189
[TBL] [Abstract][Full Text] [Related]
14. Oral Fluid and Drug Impairment: Pairing Toxicology with Drug Recognition Expert Observations.
Truver MT; Palmquist KB; Swortwood MJ
J Anal Toxicol; 2019 Sep; 43(8):637-643. PubMed ID: 31504595
[TBL] [Abstract][Full Text] [Related]
15. Trends in drivers testing positive for drugs of abuse in oral fluid from 2018 to 2021 in France.
Willeman T; Bartolli M; Jourdil JF; Vial S; Eysseric-Guérin H; Stanke-Labesque F
Forensic Sci Int; 2023 Nov; 352():111835. PubMed ID: 37748427
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral fluid contamination on two oral fluid testing systems.
Reichardt EM; Baldwin D; Osselton MD
J Anal Toxicol; 2013 May; 37(4):246-9. PubMed ID: 23471957
[TBL] [Abstract][Full Text] [Related]
17. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs.
Heltsley R; DePriest A; Black DL; Robert T; Marshall L; Meadors VM; Caplan YH; Cone EJ
J Anal Toxicol; 2011 Oct; 35(8):529-40. PubMed ID: 22004671
[TBL] [Abstract][Full Text] [Related]
18. Detection of Delta9-tetrahydrocannabinol and amphetamine-type stimulants in oral fluid using the Rapid Stat point-of-collection drug-testing device.
Röhrich J; Zörntlein S; Becker J; Urban R
J Anal Toxicol; 2010 Apr; 34(3):155-61. PubMed ID: 20406540
[TBL] [Abstract][Full Text] [Related]
19. Estimating community drug abuse by wastewater analysis.
Zuccato E; Chiabrando C; Castiglioni S; Bagnati R; Fanelli R
Environ Health Perspect; 2008 Aug; 116(8):1027-32. PubMed ID: 18709161
[TBL] [Abstract][Full Text] [Related]
20. A validated workflow for drug detection in oral fluid by non-targeted liquid chromatography-tandem mass spectrometry.
Reinstadler V; Lierheimer S; Boettcher M; Oberacher H
Anal Bioanal Chem; 2019 Feb; 411(4):867-876. PubMed ID: 30519959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
